Medical
National consultation to set MRFF medical research priorities

Medical News: A national consultation process will guide the third set of the Morrison Government’s ground-breaking Medical Research Future Fund (MRFF) Australian Medical Research and Innovation Priorities for 2020–2022.
This consultation process will ensure the MRFF continues to target national health priorities for better health outcomes.
Nadia Levin, CEO and Managing Director said “With the MRFF reaching full capitalisation of $20 billion this year, it plays as key funding role for all stages of Australian health and medical research. As we have throughout the history of MRFF, Research Australia will be engaging closely in the development of the next set of priorities to ensure that all stages of the medical research pipeline can benefit. It will be central to growing our sector and positioning Australia as a global leader in health and medical research and innovation.”
Determining future health priorities is about taking into account the burden of disease in Australians and the need to enhance the translation of research into clinical practice.
Australia’s health and medical researchers are world class and the Government continues to drive investment in ways that deliver the practical benefits of medical research and innovation to all Australians.
The landmark $20 billion MRFF is enhancing this growth in Australia’s cutting-edge health and medical research.
It is leading to new cures and treatments across Australia—saving lives and improving lives. The Australian public, organisations with expertise in health and medical research and innovation, consumer representatives, clinicians and health services managers are invited to contribute to the consultation.
Consultation is now open to inform the development of the Medical Research Future Fund (MRFF) Australian Medical Research and Innovation Priorities for 2020–22.
The Australian Medical Research Advisory Board is seeking comment from interested parties through online submissions and public webinars until 7 October 2020.
Visit the Department of Health’s Consultation Hub to see how you can comment online.
News & Trends - Pharmaceuticals

A strategic alignment for HTA Review: Professor Skerritt appointed to Medicines Australia Board
Pharma News: Professor John Skerritt has been appointed as an Independent Selected Director on the Medicines Australia Board effective 4 […]
MoreNews & Trends - MedTech & Diagnostics

Breath of change: Cystic Fibrosis Australia forges pioneering partnership with local medtech
MedTech & Diagnostics News: In a move aimed at enhancing cystic fibrosis (CF) care and support, Australian-based medical device company, […]
MoreNews & Trends - Pharmaceuticals

Does the evidence support safety concerns following CAR-T cell therapies?
Pharma News: The U.S. Food and Drug Administration (FDA) has launched an investigation into a concerning risk associated with CAR-T […]
More